For the population of T2DM-CKD, antidiabetics with renoprotective effect and their association with COVID-19 outcomes might be of special interest—SGLT-2 inhibitors and GLP-1 analogues [15, 28]. Here, SLC5A2 is linked to type 2 diabetes mellitus.